Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes

Olubukola T Idoko, Cristina Domingo, Milagritos D Tapia, Samba O Sow, Christof Geldmacher, Elmar Saathoff, Beate Kampmann, Olubukola T Idoko, Cristina Domingo, Milagritos D Tapia, Samba O Sow, Christof Geldmacher, Elmar Saathoff, Beate Kampmann

Abstract

Introduction: Although effective live attenuated yellow fever (YF) vaccines have been available for over 9 decades sporadic outbreaks continue to occur in endemic regions. These may be linked to several factors including epidemiological factors such as vector and intermediate host distribution or vaccine coverage and efficacy. The World Health Organization's research priorities include gathering systematic evidence around the potential need for booster vaccination with YF vaccine whether this follows full or fractional doses in children. Knowledge on the longevity of response to YF vaccine and the implications of this response needs to be consolidated to guide future vaccination policy. Methods: We measured anti-YF IgG by microneutralization assay in a group of 481 African infants who had received YF vaccine as part of routine EPI programmes, to explore serological protection from YF 5-6 years post YF vaccination, as well as the effect of co variates. Findings: Notably, 22.2% of the cohort had undetectable antibody concentrations, with another 7.5% revealing concentrations below the threshold of seropositivity of 0.5 IU/mL. Sex, season, country and time since vaccination did not affect the longevity of antibody concentration or having antibody concentrations above a defined threshold. Conclusion: Roughly 30% of children in this cohort did not demonstrate anti-yellow fever antibody concentrations above the defined threshold of protection, with 20% having no demonstrable antibody. Knowledge on the longevity of response to YF vaccine and the implications needs to be consolidated to guide future vaccination policy.

Keywords: 5-6 years post vaccination; protection; routine immunizations; serologic; yellow fever.

Copyright © 2020 Idoko, Domingo, Tapia, Sow, Geldmacher, Saathoff and Kampmann.

References

    1. SAGE Working Group Background Paper on Yellow Fever Vaccine (2013). Available online at:
    1. WHO Recommended Routine Immunizations for Children (2020). Available online at:
    1. Kollmann TR, Marchant A. Towards predicting protective vaccine responses in the very young. Trends Immunol. (2016) 37:523–34. 10.1016/j.it.2016.05.005
    1. WHO Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013–recommendations. Vaccine. (2015) 33:76–7. 10.1016/j.vaccine.2014.05.040
    1. World Health O . WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013. Vaccine. (2017) 35:5751–2. 10.1016/j.vaccine.2017.06.087
    1. WHO Vaccines and vaccination against yellow fever. Wkly Epidemiol Rec. (2013) 88(27):269-83.
    1. WHO . Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017-2026. Wkly Epidemiol Rec. (2017) 92:193–204.
    1. Plotkin SA. Ten yearly yellow fever booster vaccinations may still be justified. J Travel Med. (2018) 25:1–2. 10.1093/jtm/tay130
    1. de Melo AB, da Silva Mda P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, et al. . Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. (2011) 85:739–47. 10.4269/ajtmh.2011.10-0496
    1. Roukens AHE, van Halem K, de Visser AW, Visser LG. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. (2018) 169:761–5. 10.7326/M18-1529
    1. Lindsey NP, Horiuchi KA, Fulton C, Panella AJ, Kosoy OI, Velez JO, et al. . Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. (2018) 25:1–12. 10.1093/jtm/tay108
    1. Jia Q, Jia C, Liu Y, Yang Y, Qi J, Tong L, et al. . Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa. Antiviral Res. (2019) 162:1–4. 10.1016/j.antiviral.2018.12.001
    1. Idoko OT, Mohammed N, Ansah P, Hodgson A, Tapia MD, Sow SO, et al. . Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children. Exp Rev Vaccines. (2019) 18:867–75. 10.1080/14760584.2019.1640118
    1. Collaborative Group for Studies of Yellow Fever Vaccines . A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. (2015) 110:771–80. 10.1590/0074-02760150176
    1. Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, et al. . Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. (2011) 29:6327–34. 10.1016/j.vaccine.2011.05.019
    1. Roy Chowdhury P, Meier C, Laraway H, Tang Y, Hodgson A, Sow SO, et al. . Immunogenicity of yellow fever vaccine coadministered with menafrivac in healthy infants in Ghana and Mali. Clin Infect Dis. (2015) 61 (Suppl. 5):S586–93. 10.1093/cid/civ603
    1. Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, et al. . Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. Lancet Infect Dis. (2019) 19:1363–70. 10.2139/ssrn.3346514
    1. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. . Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. (2011) 364:2293–304. 10.1056/NEJMoa1003812
    1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. (2010) 17:1055–65. 10.1128/CVI.00131-10
    1. Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, et al. . A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS ONE. (2016) 11:e0149871. 10.1371/journal.pone.0149871
    1. de Menezes Martins R, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, et al. . Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine. (2018) 36:4112–7. 10.1016/j.vaccine.2018.05.041
    1. Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, Peruhype-Magalhaes V, Villela-Rezende G, Quaresma PF, et al. . Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. (2014) 14:391. 10.1186/1471-2334-14-391
    1. StataCorp Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; (2015).
    1. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. (1999) 4:867–71. 10.1046/j.1365-3156.1999.00496.x
    1. Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ. (1962) 27:699–707.
    1. Collaborative Group for Studies on Yellow Fever Vaccines . Duration of post-vaccination immunity against yellow fever in adults. Vaccine. (2014) 32:4977–84. 10.1016/j.vaccine.2014.07.021
    1. Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, et al. . Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg. (2012) 87:1112–5. 10.4269/ajtmh.2012.12-0182
    1. Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, et al. . Active Surveillance for adverse events after a mass vaccination campaign with a group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali. Clin Infect Dis. (2015) 61 (Suppl. 5):S493–500. 10.1093/cid/civ497

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir